Hoggan Scientific Extends Free Warranty Coverage From One Year to Three Years to Thank Customers
Company Extending Warranty as a Promise of Quality and a Thank You to Customers. SALT LAKE CITY, UTAH / ACCESS...
Year: 2025
Flash Survey: Hospital IT Ops Leaders Name 2026 Must-Dos Across Tight, Flat, and Growth Budgets
Operators highlight practical levers to speed AI, interoperability, and cyber resilience SAN ANTONIO, TX / ACCESS Newswire / November 3,...
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has...
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that...
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma,...
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the...
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
Agreements formalize research partnership combining InterCure’s global pharmaceutical platform with Cannasoul’s world-class analytics and scientific innovation Collaboration comes amidst reports...
IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results
Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year GuidanceReports record revenue of $21.2 million for the...
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US – European Market Put at $7 Billion
November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient...
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug...
Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment
Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types...
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward...
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing...
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology...
Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Vatica Health has merged with Cozeva, expanding leadership in value-based care enablement
ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vatica Health (“Vatica”), a Frazier Healthcare portfolio company and leader in provider-centric, prospective...
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company...
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially...
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical...